Preparations Characterized By Special Physical Form Patents (Class 424/400)
  • Patent number: 11364124
    Abstract: A build-plate with integrally-formed spinal implant constructs and a method used in forming spinal implant constructs on the build plate and machining the spinal implant constructs formed on the build plate to manufacture spinal implants is provided. The spinal implant constructs can be formed via additive manufacturing processes by adding material to an upper surface of the build plate, and then the spinal implant constructs can be subjected to subtractive manufacturing processes to form the spinal implants.
    Type: Grant
    Filed: July 26, 2019
    Date of Patent: June 21, 2022
    Assignee: WARSAW ORTHOPEDIC, INC.
    Inventors: Jonathan Dewey, Scott Renner
  • Patent number: 11357740
    Abstract: The invention provides methods for preventing, ameliorating and treating the acute and chronic forms of graft-versus-host disease (GVHD) by using Cannabidiol compositions.
    Type: Grant
    Filed: July 30, 2018
    Date of Patent: June 14, 2022
    Assignees: STERO BIOTECHS LTD., MOR RESEARCH APPLICATIONS LTD.
    Inventors: Moshe Yeshurun, Sari Prutchi Sagiv
  • Patent number: 11351125
    Abstract: The invention relates to a poly(n-butyl cyanoacrylate) nanoparticle with dual modifications, a drug delivery system comprising the nanoparticle, and a method for preparing the nanoparticle or the drug delivery system. The nanoparticle is modified with a first modifier and a second modifier on the surface, the first modifier is a hydrophilic polymer, and the second modifier is an amino acid and/or a lipid. The invention further relates to a use of the nanoparticle in promoting drug penetration across the blood brain barrier in a subject.
    Type: Grant
    Filed: February 21, 2017
    Date of Patent: June 7, 2022
    Assignee: Xuanwu Hospital of Capital Medical University
    Inventors: Lan Zhang, Xiao Hu, Lin Li
  • Patent number: 11351158
    Abstract: The invention provides systems and methods for increased clinical efficacy of rifabutin against A. baumannii. The invention takes advantage of the discovery of a ferric-coprogen (FhuE) receptor that is responsible for the uptake of rifabutin into A. baumannii cells. Methods preferably include obtaining a sample from a patient suspected of having an infection; performing a test on the sample to identify an infection of A. baumannii in the patient; and providing a formulation of rifabutin for treating the patient that, when administered to the patient, maximizes a resultant AUC and/or Cmax. The method may include administering the formulation of rifabutin to the patient. Preferably the formulation is delivered to the patient, e.g., by intravenous injection and results in a Cmax is that greater than about 2 mg/L and optionally less than about 50 mg/L.
    Type: Grant
    Filed: August 3, 2020
    Date of Patent: June 7, 2022
    Assignee: BIOVERSYS AG
    Inventors: Glenn E. Dale, Sergio Lociuro, Christian Kemmer, Vincent Trebosc, Marc Gitzinger
  • Patent number: 11351099
    Abstract: A skincare rejuvenation composition, adapted at least for tactile use, consists essentially of a skincare rejuvenation ingredient, a skin exfoliation ingredient, an acidity balancing ingredient, a sunscreen composition and an emulsifier. The skincare rejuvenation ingredient has a first weight percentage, the skin exfoliation ingredient has a second weight percentage, and the acidity balancing ingredient has a third weight percentage, whereby each of the first weight percentage, the second weight percentage, and the third weight percentage are substantially equal. As an example, the skincare rejuvenation ingredient may be retinol, the skin exfoliation ingredient may be glycolic acid, and the acidity balancing ingredient may be hyaluronic acid.
    Type: Grant
    Filed: September 4, 2020
    Date of Patent: June 7, 2022
    Assignee: ELYSE ENTERPRISES LLC
    Inventor: Hillary Hayman
  • Patent number: 11351530
    Abstract: A photocatalyst can be regenerated with increasing efficiency, turnover number and turnover frequency in the presence of air by irradiating the photocatalyst with a first range of wavelengths of light that excite the photocatalyst to an intermediate and irradiating the intermediate with a second range of wavelengths of light that turns the intermediate to the photocatalyst.
    Type: Grant
    Filed: November 6, 2017
    Date of Patent: June 7, 2022
    Assignee: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
    Inventors: Hadley Sikes Johnson, Hector Alan Aguirre Soto
  • Patent number: 11344484
    Abstract: The invention relates to oil-in-water emulsion in which specific oils (e.g., lauric oils) are used in the oil phase while surprisingly maintaining excellent transparency. In one aspect, said emulsions comprise fatty acid in oil phase. The invention comprises an energy efficient process for making said fatty acid containing transparent nanoemulsions.
    Type: Grant
    Filed: January 21, 2019
    Date of Patent: May 31, 2022
    Assignee: CONOPCO, INC.
    Inventor: Congling Quan
  • Patent number: 11344537
    Abstract: The invention provides formulations containing highly concentrated solutions of rifabutin and methods of making such formulations. The invention also provides methods of using such formulations to treat a bacterial infection in a subject.
    Type: Grant
    Filed: August 3, 2020
    Date of Patent: May 31, 2022
    Assignee: BIOVERSYS AG
    Inventors: Sergio Lociuro, Stefano Biondi, Glenn E. Dale, Marilyne Bourotte, Marc Gitzinger
  • Patent number: 11337961
    Abstract: Disclosed herein are self-emulsifying compositions and formulations of Dimdolylmethane (“DIM”) and certain derivatives of DIM, their uses and methods of making. In particular, the disclosed compositions comprise a DIM-related indole as an active agent and a carrier, wherein the carrier comprises a solvent, one or more surfactants with an HLB of greater than 7, and one or more co-surfactants with an HLB equal to or less than 7. In certain aspects of the invention, the compositions disclosed herein show improved bioavailability.
    Type: Grant
    Filed: September 1, 2020
    Date of Patent: May 24, 2022
    Assignee: Bioresponse, L.L.C.
    Inventors: Michael A. Zeligs, Irwin C. Jacobs
  • Patent number: 11338007
    Abstract: Disclosed are pharmaceutical compositions comprising three antiviral compounds. In particular, the pharmaceutical compositions comprise an effective amount of velpatasvir, an effective amount of sofosbuvir, and an effective amount of voxilaprevir. Also disclosed are methods of use for the pharmaceutical composition.
    Type: Grant
    Filed: June 1, 2017
    Date of Patent: May 24, 2022
    Assignee: Gilead Sciences, Inc.
    Inventors: Ben Chal, Elham Nejati, Rowchanak Pakdaman, Dimitrios Stefanidis
  • Patent number: 11331256
    Abstract: The present disclosure relates to a cosmetic composition for blocking fine dust. The composition according to the present disclosure can fundamentally prevent problems due to fine dust by reducing the attachment rate of fine dust attached to skin.
    Type: Grant
    Filed: October 18, 2017
    Date of Patent: May 17, 2022
    Assignee: LG HOUSEHOLD & HEALTH CARE LTD.
    Inventors: Seong-Cheon Lee, Hyeong-Jin Cho, Ki-Young Kim, Eui-Taek Jeong, Yu-Mi Kim, Nae-Gyu Kang
  • Patent number: 11331338
    Abstract: The invention provides a hydrogen sulfide releasing polymer compound having a polysaccharide backbone, wherein the compound has at least two substructures, and wherein said substructures are capable of releasing hydrogen sulfide by thiol activation as well as uses thereof. Additionally, a method of treatment and prevention of a skin condition, an ocular disease or osteoarthritis is provided.
    Type: Grant
    Filed: November 7, 2017
    Date of Patent: May 17, 2022
    Assignee: CROMA-PHARMA GESELLSCHAFT M.B.H.
    Inventors: Martin Prinz, Martin Hoffer
  • Patent number: 11324678
    Abstract: This invention provides core shell silica particles, wherein each core shell silica particle comprises a silica core, and a surface of the silica core etched with group I metal silicate. These core shell silica particles have high surface charge density and anti-bacterial activity. Also provided are compositions comprising core shell silica particles, process of making the core shell silica particles and methods of reducing or inhibiting bacterial activity by administering the core shell silica particles or compositions thereof.
    Type: Grant
    Filed: July 16, 2019
    Date of Patent: May 10, 2022
    Assignee: Colgate-Palmolive Company
    Inventors: Guisheng Pan, Suman Chopra
  • Patent number: 11324699
    Abstract: Disclosed are various embodiments of lipid multiparticulate compositions comprising at least one active agent, a low flow point excipient, and a high flow point excipient.
    Type: Grant
    Filed: November 24, 2015
    Date of Patent: May 10, 2022
    Assignee: Capsugel Belgium NV
    Inventors: Christopher Diorio, John Lokhnauth, Chang Lee
  • Patent number: 11324707
    Abstract: Disclosed herein are immediate release oral dosage forms that contain abuse-deterrent and abuse-resistant features. In particular, the disclosed dosage forms can provide deterrence of abuse by ingestion of multiple individual doses. The disclosed dosage forms can likewise provide protection from overdose in the event of accidental or intentional ingestion of multiple individual doses. The dosage forms may also exhibit abuse resistant properties when physically manipulated, and also when physically manipulated and then administered in a manner not consistent with oral dosing. The dosage forms may also exhibit abuse resistant properties when administered in a manner intended to result in administration of the esketamine in a higher than therapeutic dose.
    Type: Grant
    Filed: May 7, 2020
    Date of Patent: May 10, 2022
    Assignee: CLEXIO BIOSCIENCES LTD.
    Inventors: Derek Moe, Randal Seburg, Sagar Rane
  • Patent number: 11328792
    Abstract: The present invention provides a device, method, and program for detection of a biomarker candidate that may be used in a diagnosis of a pre-disease state indicating a transition from a healthy state to a disease state. Biological samples are collected from a subject to be measured at different times. Statistical data is obtained by aggregating measurement data obtained in measurement on collected biological samples. Thereafter, a process of obtaining high-throughput data (s1), a process of choosing differential biological molecules (s2), a process of clustering (s3), a process of choosing a DNB candidate (s4), and a process of identifying a DNB by significance analysis (s5) are carried out.
    Type: Grant
    Filed: February 12, 2013
    Date of Patent: May 10, 2022
    Assignee: Japan Science and Technology Agency
    Inventors: Kazuyuki Aihara, Luonan Chen, Rui Liu, Zhiping Liu, Meiyi Li
  • Patent number: 11324852
    Abstract: The present invention relates to coated silk films. Further, the present invention relates to pharmaceutical or cosmetic compositions comprising the coated silk films. Furthermore, the present invention relates to coated silk films or pharmaceutical compositions comprising the coated silk films for use in medicine. In addition, the present invention relates to methods of producing the coated silk films.
    Type: Grant
    Filed: January 29, 2015
    Date of Patent: May 10, 2022
    Assignee: Amsilk GmbH
    Inventors: Gerhard Winter, Elisa Agostini, Julia Engert, Lin Romer, Ute Slotta
  • Patent number: 11318203
    Abstract: The invention provides a liquid-dispersible powder comprising nanoscale grains of matrix embedded with one or more isolated nanoparticles and a composition for the magnetic nanoparticle hyperthermia (MNH) treatment of tumours comprising nanoscale grains of matrix material containing one or more isolated nanoparticles. The invention also provides a method of production of a liquid-dispersible powder described herein, the method comprising the steps of providing nanoparticles prepared under ultra-high vacuum (UHV) gas phase conditions; co-depositing the nanoparticles within a matrix material under UHV gas phase conditions; and grinding the film to a fine powder comprising grains of groups of matrix material isolated nanoparticles.
    Type: Grant
    Filed: July 18, 2017
    Date of Patent: May 3, 2022
    Assignee: Ubicoat Ltd
    Inventors: Robert Davidson Binns, Patrick William John Kinmont
  • Patent number: 11318149
    Abstract: The present disclosure provides, among other things, compositions and methods useful for inhibiting biofilm-forming bacteria. For example, the compositions and methods described herein can be used to inhibit the proliferation, viability, and/or biofilm-forming activity, of biofilm-forming bacteria.
    Type: Grant
    Filed: September 26, 2019
    Date of Patent: May 3, 2022
    Assignee: Board of Trustees of Michigan State University
    Inventors: Christopher Waters, Michael Maiden
  • Patent number: 11318232
    Abstract: The invention relates to balloon coatings and their use in delivering drugs via a drug-eluting balloon. The delivery can be, e.g., to a vessel wall.
    Type: Grant
    Filed: February 21, 2020
    Date of Patent: May 3, 2022
    Assignee: Interface Biologics, Inc.
    Inventors: Bernadette Ilagan, Yulin Wang, Georgios Rizis, Bingqing Yang, Wendy Alison Naimark
  • Patent number: 11311482
    Abstract: Topical pharmaceutical compositions include tazarotene or a pharmaceutically acceptable salt of tazarotenic acid and an oil-in-water emulsion vehicle that forms a lotion. The compositions are used to treat skin diseases, such as acne vulgaris.
    Type: Grant
    Filed: November 2, 2018
    Date of Patent: April 26, 2022
    Assignee: BAUSCH HEALTH US, LLC
    Inventors: Arturo Angel, Radhakrishnan Pillai
  • Patent number: 11304922
    Abstract: A pharmaceutical composition of micronutrients were tried to improve cognitive brain function, brain health and nervous system functions. Combination consisting of Avena sativa (green oat straw extract), Coenzyme Q10, NAD+, American Ginseng, and Pyrroloquinoline quinone in physiological dose range shows multiple simultaneous positive effects in supporting key functions in cells building our nervous system essential for optimum mental and/or cognitive health including protecting nervous system cells against various damaging factors, increasing ATP production, stimulating mitochondria biogenesis, increasing mitochondrial membrane potential, increasing mitochondrial functions (Complex I activity), exhibiting anti-inflammatory capacity and increased BDNF secretion.
    Type: Grant
    Filed: December 15, 2021
    Date of Patent: April 19, 2022
    Inventor: Matthias W Rath
  • Patent number: 11304918
    Abstract: The present invention is directed to methods and compositions for the treatment of diverticulosis. It is more specifically directed to compositions including L-glutamine, its salts, or its derivatives, and uses of such compositions in the treatment of diverticulosis. In a method aspect, the present invention provides a method of treating diverticulosis. The method includes ingestion of 0.05 g/kg body weight to 10.0 g/kg body weight of L-glutamine, an L-glutamine salt or an L-glutamine derivative per day by a person who has diverticulosis.
    Type: Grant
    Filed: February 11, 2019
    Date of Patent: April 19, 2022
    Assignee: Emmaus Medical, Inc.
    Inventor: Yutaka Niihara
  • Patent number: 11304921
    Abstract: A pharmaceutical composition of micronutrients were tried to improve brain health and nervous system functions. Combination of L-theanine, Rhodiola rosea, Acetyl L-Carnitine (ALCAR), Bacopa monnieri, Mucuna pruriens, NAD+, Rose hips extract (trans-tiliroside), American Ginseng, Pyrroloquinoline quinone, Gotu Kola in physiological dose range shows multiple simultaneous positive effects in supporting key functions in cells building our nervous system essential for optimum mental and/or cognitive health including protecting nervous system cells against various damaging factors, increasing ATP production, stimulating mitochondria biogenesis, increasing mitochondrial membrane potential, increasing mitochondrial functions (Complex I activity), exhibiting anti-inflammatory capacity and increased BDNF secretion.
    Type: Grant
    Filed: December 13, 2021
    Date of Patent: April 19, 2022
    Inventor: Matthias W Rath
  • Patent number: 11298318
    Abstract: Ultra-small Lipid Structures (USLS) with an average mean particle diameter of less than 100 nm are made using a single step process by diluting a hydro-organic solution containing lipids and passenger compounds. These particles are capable of sequestering the passenger molecules and self-assemble in a single process step into USLS. The USLS have applications in, for example, agricultural, cosmetics, pharmaceutical and food and beverage industries.
    Type: Grant
    Filed: April 13, 2016
    Date of Patent: April 12, 2022
    Assignee: FOUNTAIN TECHNOLOGIES INTERNATIONAL, LLC
    Inventor: Michael Fountain
  • Patent number: 11291642
    Abstract: The present invention provides dimethyl fumarate (DMF) particles and methods of preparing the DMF particles. Also provided is DMF coated particles comprising DMF particles coated with an enteric coating. The invention also provides various dosage forms and methods of treating a disease or disorder (e.g., multiple sclerosis).
    Type: Grant
    Filed: June 15, 2016
    Date of Patent: April 5, 2022
    Assignee: BIOGEN MA INC.
    Inventors: Pierre Boulas, Erwin Irdam, Shyam B. Karki, William F. Kiesman, Cheuk-Yui Leung, Yiqing Lin, Andrea Trementozzi, Peter Zawaneh
  • Patent number: 11292827
    Abstract: Disclosed is a method of producing high-concentration collagen for use as a medical material, including: washing tissue of a mammal; subjecting the washed tissue to crushing and immersion in ethyl alcohol; subjecting the tissue to enzymatic treatment with stirring in purified water containing phosphoric acid and pepsin; adding sodium chloride to the collagen subjected to enzymatic treatment, performing stirring, and aggregating collagen; dissolving the aggregated collagen in purified water to give a collagen solution, which is then filtered using a filter and concentrated by removing the pepsin, low-molecular-weight material, and sodium chloride from the collagen solution using a tangential flow filtration device; subjecting the concentrated collagen to sterile filtration, aggregating the collagen using a pH solution in a neutralization tank, and concentrating the collagen by removing a non-aggregated solution; and concentrating the concentrated collagen using a centrifuge and stirring the concentrated collag
    Type: Grant
    Filed: December 11, 2014
    Date of Patent: April 5, 2022
    Assignee: SEWONCELLONTECH CO., LTD.
    Inventors: Cheong Ho Chang, Hyeong Woo Jeong, Ji Chui Yoo, Se Ken Yeo, Dong Sam Suh
  • Patent number: 11293915
    Abstract: A gel composition that forms a three dimensional gel microenvironment that is formed of an adhesive protein, a maleimide-functionalized poly alkylene oxide, a linking agent and a nanoparticle, the components forming an interpenetrating network that exhibits improved mechanical and biochemical properties, as well as creates a favorable microenvironment for cellular growth and proliferation. The gel composition also creates a favorable microenvironment for testing various agents on normal or diseased cells, including chemotherapeutic agents on cancer cells or other diseased cells.
    Type: Grant
    Filed: May 8, 2015
    Date of Patent: April 5, 2022
    Assignee: CORNELL UNIVERSITY
    Inventors: Ankur Singh, Ravi G. Patel
  • Patent number: 11285305
    Abstract: The invention relates to an implantable device suitable for being fixed in a fixation position to a wall of a patient's stomach, the implantable device being accommodated in the stomach when the implantable device is in the fixation position, the implantable device being characterised in that it comprises a reserve of an active substance and an injector suitable for administering the active substance to the patient.
    Type: Grant
    Filed: December 7, 2017
    Date of Patent: March 29, 2022
    Assignees: UNIVERSITE GRENOBLE ALPES, CENTRE HOSPITALIER UNIVERSITAIRE GRENOBLE ALPES
    Inventors: Philippe Cinquin, Patrick Tuvignon
  • Patent number: 11285099
    Abstract: The present disclosure relates to pharmaceutical compositions containing phenytoin or phenytoin sodium for use in topical pain relief. Use of the pharmaceutical composition of the disclosure reduces peripheral neuropathic pain. The topical pharmaceutical compositions of the disclosure containing phenytoin or phenytoin sodium, surprisingly reduce peripheral neuropathic pain considerably, especially and preferably in the conditions, characterized by a low to moderate grade of peripheral neurogenic inflammation, such as small fiber neuropathy, diabetic neuropathy, chronic idiopathic axonal polyneuropathy, post-herpetic neuralgia, trigeminus neuralgia, chemotherapy induced polyneuropathy, traumatic neuropathies, compression neuropathies, and infectious neuropathies in remission, according to the disclosure.
    Type: Grant
    Filed: December 6, 2017
    Date of Patent: March 29, 2022
    Assignees: Topical Innovations B.V.
    Inventors: David Jos Kopsky, Jan Marius Keppel Hesselink
  • Patent number: 11278625
    Abstract: The instant invention relates to new film-forming compositions based on starchy material, comprising isosorbide. The instant invention also relates to products made from the film-forming compositions of the invention, in particular hard and soft capsules shells, and to methods for the manufacture of such products.
    Type: Grant
    Filed: August 5, 2016
    Date of Patent: March 22, 2022
    Inventors: Bernard Pora, Yong Miao, Jovin Hasjim
  • Patent number: 11278626
    Abstract: Aspects of the present disclosure include compositions having a plurality of individual polymeric nanowires. Individual polymeric nanowires according to embodiments include a bioactive compound. Methods for preparing and methods for administering the subject compositions of individual polymeric nanowires to a subject are also described. Kits having one or more components for practicing the subject methods are also provided.
    Type: Grant
    Filed: October 4, 2017
    Date of Patent: March 22, 2022
    Assignee: The Regents of the University of California
    Inventors: Colin R. Zamecnik, Tejal A. Desai
  • Patent number: 11266765
    Abstract: Provided herein are constructs of micro-aggregate multicellular, minimally polarized grafts containing Leucine-rich repeat-containing G-protein coupled Receptor (LGR) expressing cells for wound therapy applications, tissue engineering, cell therapy applications, regenerative medicine applications, medical/therapeutic applications, tissue healing applications, immune therapy applications, and tissue transplant therapy applications which preferably are associated with a delivery vector/substrate/support/scaffold for direct application.
    Type: Grant
    Filed: July 14, 2017
    Date of Patent: March 8, 2022
    Assignee: PolarityTE, Inc.
    Inventor: Denver M. Lough
  • Patent number: 11266577
    Abstract: An emulsion comprising a continuous aqueous phase and a dispersed fatty phase in the form of drops, or conversely, wherein the drops comprise a shell formed of at least one anionic polymer comprising at least one carboxylic acid function and at least one cationic polymer comprising at least two amine functional groups, wherein the quantity of amine functional groups provided by the cationic polymer in the fatty phase is between 0.2 ?mol and 10.5 ?mol per gram of fatty phase.
    Type: Grant
    Filed: September 16, 2016
    Date of Patent: March 8, 2022
    Assignee: CAPSUM
    Inventors: Mathieu Goutayer, Amélie Pujol
  • Patent number: 11266652
    Abstract: The present disclosure is directed to a method of treating prediabetes or type 1 or type 2 diabetes mellitus comprising administering to a subject in need thereof an effective amount of imeglimin, wherein the subject has chronic kidney disease.
    Type: Grant
    Filed: March 9, 2020
    Date of Patent: March 8, 2022
    Assignee: POXEL SA
    Inventors: Bill Symonds, Steve Piscitelli, Karen Segal, Ruby Holder, Sophie Bozec, Sebastien Bolze, Pascale Fouqueray, Christophe Arbet-Engels, Julie Dubourg, Paul Strumph, Brandon Dale Swift, Margaret Smith Fletcher
  • Patent number: 11266580
    Abstract: The invention relates to oil-in-water emulsion in which specific oils (e.g., lauric oils) are used in the oil phase while surprisingly maintaining excellent transparency. In one aspect, said emulsions comprise fatty acid in oil phase. In a separate co-pending application, the invention comprises an energy efficient process for making said fatty acid containing transparent nanoemulsions.
    Type: Grant
    Filed: January 21, 2019
    Date of Patent: March 8, 2022
    Assignee: CONOPCO, INC.
    Inventor: Congling Quan
  • Patent number: 11260023
    Abstract: The present disclosure provides topical compositions of rofecoxib and methods of making said compositions. The present disclosure also provides methods of using topical compositions of rofecoxib to treat inflammation.
    Type: Grant
    Filed: February 23, 2021
    Date of Patent: March 1, 2022
    Assignee: BRIORI BIOTECH, LLC
    Inventor: Robert Bruce Register
  • Patent number: 11260000
    Abstract: The present invention relates to a composition, preferably a cosmetic composition, comprising: (a) at least one oil; (b) at least one polyglyceryl fatty acid ester, preferably with a polyglyceryl moiety derived from 2 to 6 glycerins; (c) at least one compound selected from the group consisting of resorcinol and resorcinol derivatives; and (d) water. The composition according to the present invention can be in the form of a nano- or micro-emulsion, or can have a lamellar structure or a lamellar phase, with better transparency and stability.
    Type: Grant
    Filed: June 10, 2015
    Date of Patent: March 1, 2022
    Assignee: L'OREAL
    Inventors: Yuichi Ikeda, Maki Koide, Anne-Laure Bernard, Chantal Jouy
  • Patent number: 11252984
    Abstract: Methods for treatment of chronic liver disease and reversing liver fibrosis are provided. These treatments may be achieved using a medical food composition. The medical food is configured specifically for those having chronic liver disease to provide for specific nutritional requirements caused by the chronic liver disease. Testing of the treated patient allows for tracking of progress and to determine if the liver fibrosis is reversed.
    Type: Grant
    Filed: August 21, 2017
    Date of Patent: February 22, 2022
    Inventor: Michael Hudnall
  • Patent number: 11253833
    Abstract: A facility for industrial drying and/or encapsulation of thermolabile substances comprising at least one injection unit (1) wherein the thermolabile substance is introduced, an encapsulating material when the facility is used to encapsulate, a solvent, additives and an injection gas flow for obtaining droplets from the thermolabile substance. It further comprises a drying unit (2) through which the droplets and a drying gas are introduced for evaporating the solvent and comprises a collection unit (3) configured to separate the microcapsules generated from the drying gas and which is selected from a cartridge filter collector, a cyclone collector or a combination of the two. It also describes a method for the industrial encapsulation of thermolabile substances which is carried out at the proposed facility.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: February 22, 2022
    Assignees: BIOINICIA, S.L., CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)
    Inventors: José María Lagaron Cabello, Sergio Castro Reina, José Manuel Valle, David Galan Nevado
  • Patent number: 11253478
    Abstract: This invention is directed to reduction of flake-like aggregation in nanoparticulate compositions. Also encompassed by the invention are compositions comprising a nanoparticulate active agent, at least one surface stabilizer and a flake-like aggregation reducing agent, such as a buffer and a sugar. The nanoparticulate active agent compositions comprise particles of the active agent having an effective average particle size of less than about 2000 nm.
    Type: Grant
    Filed: May 4, 2018
    Date of Patent: February 22, 2022
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Niels P. Ryde, Peter Snyder, Wei Liu, David M. Slifer
  • Patent number: 11247187
    Abstract: Provided are a pickering emulsion including: 0.01-20 wt % of particles having an average particle diameter of 10 nm-100 ?m, and 0.01-20 wt % of a non-ionic water-soluble polymer, wherein the particles are positioned on an oil droplet surface, and a method of preparing the same.
    Type: Grant
    Filed: April 25, 2016
    Date of Patent: February 15, 2022
    Assignee: KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Siyoung Choi, Kyu Han Kim
  • Patent number: 11241403
    Abstract: Ketogenic compositions including a plurality of beta-hydroxybutyrate (BHB) salts are formulated to induce or sustain ketosis in a subject to which the ketogenic compositions are administered. The BHB mixed salt is formulated to provide a biologically balanced set of cationic electrolytes and avoid detrimental health effects associated with imbalanced electrolyte ratios. A ketogenic composition includes BHB salts selected from sodium, potassium, calcium, and magnesium salts. The BHB composition may also include transition metal cations (e.g., zinc or iron), one or more BHB-amino acid salts, a short-, medium-, or long-chain fatty acid source, vitamins, minerals, flavorants, or other excipients.
    Type: Grant
    Filed: March 11, 2021
    Date of Patent: February 8, 2022
    Assignee: AXCESS GLOBAL SCIENCES, LLC
    Inventor: Gary Millet
  • Patent number: 11241388
    Abstract: Compositions and methods for combination therapy are provided. The compositions comprise a multiple unit dosage form having both a therapeutic agent and a nutritional supplement. The combination therapy is useful for restoring a nutrient depletion associated with a particular disease state. Additionally, the combination therapy can prevent or attenuate the depletion of a nutrient caused, in whole or in part, by the co-administrated therapeutic drug. Methods of manufacturing the formulations are likewise described.
    Type: Grant
    Filed: July 29, 2019
    Date of Patent: February 8, 2022
    Assignee: JDS Therapeutics, LLC
    Inventor: James R. Komorowski
  • Patent number: 11241316
    Abstract: A medical implant structure is provided comprising a substrate 10 with at least a first surface and a second surface that surfaces differ from one another with regard to at least one property in relation to biological material.
    Type: Grant
    Filed: March 26, 2020
    Date of Patent: February 8, 2022
    Assignee: PICOSUN OY
    Inventors: Niku Oksala, Marko Pudas
  • Patent number: 11234952
    Abstract: A pharmaceutical composition of micronutrients were tried to improve brain health and nervous system functions. Various combinations of formulas were used. Formulas 12, 10 and 5 shows multiple simultaneous positive effects in supporting key functions in cells building our nervous system essential for optimum mental health including protecting nervous system cells against various damaging factors, increasing ATP production, stimulating mitochondria biogenesis, increasing mitochondrial membrane potential, increasing mitochondrial functions (Complex I activity), exhibiting anti-inflammatory capacity and increased BDNF secretion.
    Type: Grant
    Filed: July 12, 2021
    Date of Patent: February 1, 2022
    Inventor: Matthias W Rath
  • Patent number: 11234937
    Abstract: The present invention relates to pharmaceutical composition, comprising certain phosphate binder particles having a certain particle size distribution, a process for the manufacture of the pharmaceutical composition and the use of sucroferric oxyhydroxide having a certain particle size distribution for the manufacture of a pharmaceutical composition.
    Type: Grant
    Filed: March 16, 2020
    Date of Patent: February 1, 2022
    Assignee: Vifor Fresenius Medical Care Renal Pharma Ltd.
    Inventors: Laurent Chofflon, Erik Philipp
  • Patent number: 11234932
    Abstract: Embodiments of the present invention are directed to particles having a Bryoid and a HDAC inhibitor for the treatment of latent viral disease.
    Type: Grant
    Filed: November 27, 2019
    Date of Patent: February 1, 2022
    Assignee: APHIOS CORPORATION
    Inventor: Trevor Percival Castor
  • Patent number: 11234938
    Abstract: The present invention relates to pharmaceutical composition, comprising certain phosphate binder particles having a certain particle size distribution, a process for the manufacture of the pharmaceutical composition and the use of sucroferric oxyhydroxide having a certain particle size distribution for the manufacture of a pharmaceutical composition.
    Type: Grant
    Filed: March 16, 2020
    Date of Patent: February 1, 2022
    Assignee: Vifor Fresenius Medical Care Renal Pharma Ltd.
    Inventors: Laurent Chofflon, Erik Philipp
  • Patent number: 11225652
    Abstract: Provided are methods for lyophilization of an aqueous thrombin solution, thrombin solutions for use in such lyophilization methods, and solid thrombin compositions produced by such methods.
    Type: Grant
    Filed: October 8, 2019
    Date of Patent: January 18, 2022
    Assignee: Omrix Biopharmaceuticals Ltd.
    Inventors: Roberto Meidler, Oleg Belyaev, Liliana Bar, Israel Nur